MAIA Biotechnology, Inc. (MAIA) stock
MAIANYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$1.30+0.05 (+4.00%)
Close on Nov 18, 2026Market cap $79.07MP/E –Yield –
MAIA Biotechnology r&d expenses
Research and development expenses are spending on new products and technology.
MAIA Biotechnology's R&D Expenses for the twelve months ending Sep 30, 2025 was $15.63M, up 45.3% year over year. For fiscal 2025 it was $453.75K, down 95.5% from the year before. The highest annual figure on record is $11.11M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $453.75K | -95.5% |
| FY2024 | Dec 31, 2024 | $10.01M | -9.9% |
| FY2023 | Dec 31, 2023 | $11.11M | +24.4% |
| FY2022 | Dec 31, 2022 | $8.93M | +155.5% |
| FY2021 | Dec 31, 2021 | $3.50M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.64M | +76.4% |
| Q1 FY2026 | Mar 31, 2026 | $43.65K | -98.5% |
| Q3 FY2025 | Sep 30, 2025 | $6.36M | +138.4% |
| Q2 FY2025 | Jun 30, 2025 | $3.11M | +51.6% |
| Q1 FY2025 | Mar 31, 2025 | $3.20M | +37.8% |
| Q4 FY2024 | Dec 31, 2024 | $2.97M | -20.1% |
| Q3 FY2024 | Sep 30, 2024 | $2.67M | +2.6% |
| Q2 FY2024 | Jun 30, 2024 | $2.05M | -21.0% |
| Q1 FY2024 | Mar 31, 2024 | $2.32M | +5.7% |
| Q4 FY2023 | Dec 31, 2023 | $3.72M | +55.3% |
| Q3 FY2023 | Sep 30, 2023 | $2.60M | +10.9% |
| Q2 FY2023 | Jun 30, 2023 | $2.60M | +22.6% |
| Q1 FY2023 | Mar 31, 2023 | $2.20M | +5.7% |
| Q4 FY2022 | Dec 31, 2022 | $2.39M | +58.7% |
| Q3 FY2022 | Sep 30, 2022 | $2.34M | +116.6% |
| Q2 FY2022 | Jun 30, 2022 | $2.12M | +229.1% |
| Q1 FY2022 | Mar 31, 2022 | $2.08M | – |
| Q4 FY2021 | Dec 31, 2021 | $1.51M | – |
| Q3 FY2021 | Sep 30, 2021 | $1.08M | – |
| Q2 FY2021 | Jun 30, 2021 | $643.99K | – |
See a number that looks wrong?